

## **FP1056 TREATMENT OF LARGE SUPERFICIAL BASAL CELL CARCINOMA ON THE SCALP WITH 5% IMIQUIMOD**

**S. T. Kim<sup>1</sup>, J. W. Baek<sup>1</sup>, T. K. Kim<sup>1</sup>, J. W. Lee<sup>1</sup>, H. J. Roh<sup>1</sup>, Y. S. Jeon<sup>1</sup>, K. S. Suh<sup>1</sup>**  
<sup>1</sup>Department of Dermatology, Kosin University College of Medicine, Busan, South Korea

*Background: Imiquimod is immune response modifier that has antiviral and antitumoral activity through the Toll-like receptor 7, 8 pathway. It has been used to treat superficial basal cell carcinomas (sBCC), actinic keratosis, genital wart. sBCCs are rare and predominantly located on the trunk. We report a case of large sBCC localized on the scalp treated with 5% imiquimod.*

*Case report: A 71-year-old female patient presented with a scaly some crusted erythematous to violaceous measuring about 6.5 x 6.5 cm plaque with slightly raised irregular border on the scalp for 4 years. Skin biopsy showed features of sBCC such as basaloid tumor cell budding, peripheral palisading, stromal retraction. The lesion was big size and she disagreed to surgical approaches. Thus, we considered non-surgical treatment option. She was instructed to apply imiquimod, 5 to 7 times per week for 12 weeks and regularly examined every second week. During treatment, adverse skin reactions were observed such as skin burning, erythema, crusts but was relatively milder than our expectation. After 12 weeks, the first following targeted biopsy revealed remarkable regression of tumor cells but yet remained partially. After Supplementary application of imiquimod 3 times per week for 4 weeks, the posttreatment biopsy showed tumor cells were completely cleared and no recurrence for the following one year.*

*Conclusion: Although this case was successfully treated with 5% imiquimod, we think that the complete remission was obtained somewhat lately than previously reported studies. So we postulate that the factors of delaying treatment response are thicker skin layer of scalp, different tumor biology at various anatomical sites and relatively mild inflammatory reaction at the imiquimod applied lesion. However, further studies are needed to clarify our presumptions mentioned above.*

**References:** 1. LinksEigentler TK, Kamin A, Weide BM, Breuninger H, Caroli UM, Möhrle M, Radny P, Garbe C. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. *J Am Acad Dermatol.* 2007 Oct;57(4):616-21. Epub 2007 Jul 3  
2. Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrándiz C, Garcia Diez A, Tebbs V, McRae S. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. *Br J Dermatol.* 2005 May;152(5):939-47.  
3. Chen TM, Rosen T, Orengo I. Treatment of a large superficial basal cell carcinoma with 5% imiquimod: a case report and review of the literature. *Dermatol Surg.* 2002 Apr;28(4):344-6.  
4. LinksYazici AC, Unal S, Ikizoglu G, Kokturk A, Baz K, Cinel L, Koca A. Superficial basal cell carcinoma of the scalp mimicking seborrhoeic dermatitis. *Scand J Plast Reconstr Surg Hand Surg.* 2006;40(1):54-6